A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
A phase 1/2 trial of IPN01194 in melanoma, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma and colorectal cancer, run by Ipsen, active and no longer recruiting.
Overview
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT06305247 by Ipsen, with 36 participants enrolled, started 2024-04-03 and due to reach its primary completion in 2028-03-20. Interventions recorded: IPN01194.
Similar pages
not linked directly; found by shared links- TrialStudy of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Shares Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
- TrialA Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Shares Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma, Melanoma and the tag pipeline.
- TrialA Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
Shares Ipsen and the tag pipeline.
- TrialA Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
Shares Ipsen and the tag pipeline.
- TrialA Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
Shares Ipsen and the tag pipeline.
- TrialPhase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
- TrialA Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Shares Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.